Simoladagene Autotemcel Lentiviral Vector

Severe Combined Immunodeficiency, Autosomal Recessive, T Cell-Negative, B Cell-Negative, NK Cell-Negative, Due To Adenosine Deaminase Deficiency

University of California, Los Angelesgene_therapyUnknownActive

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

0 Active assets in the Severe Combined Immunodeficiency, Autosomal Recessive, T Cell-Negative, B Cell-Negative, NK Cell-Negative, Due To Adenosine Deaminase Deficiency cohort.

Asset / Sponsor	Phase	Rating
Adagen Leadiant Biosciences, Inc.	Phase 3	BB
Elapegademase Leadiant Biosciences, Inc.	Phase 3	BB
Peg-Ada Great Ormond Street Hospital for Children NHS Foundation Trust	Phase 1/2	CCC
Busulfanum Great Ormond Street Hospital for Children NHS Foundation Trust	Phase 1/2	CCC
Infusion Of Autologous Efs-Ada Lv Cd34+ Cells Great Ormond Street Hospital for Children NHS Foundation Trust	Phase 1/2	CCC
Cyclosporin A Fred Hutchinson Cancer Center	Phase 1	CC

Same molecule, other indications

Simoladagene Autotemcel Lentiviral Vector is also rated in:

severe combined immunodeficiencyActive

Indicative · Unknown

30 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →